1
|
Anderson LJ, Yin C, Burciaga R, Lee J, Crabtree S, Migula D, Geiss-Wessel K, Liu HM, Graf SA, Chauncey TR, Garcia JM. Assessing Cachexia Acutely after Autologous Stem Cell Transplant. Cancers (Basel) 2019; 11:E1300. [PMID: 31487803 PMCID: PMC6769803 DOI: 10.3390/cancers11091300] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2019] [Revised: 08/30/2019] [Accepted: 08/30/2019] [Indexed: 01/28/2023] Open
Abstract
Autologous hematopoietic stem cell transplantation (AHCT) is an accepted strategy for various hematologic malignancies that can lead to functional impairment, fatigue, muscle wasting, and reduced quality of life (QOL). In cancer cachexia, these symptoms are associated with inflammation, hypermetabolism, and decreased anabolic hormones. The relative significance of these factors soon after AHCT setting is unclear. The purpose of this study was to characterize the acute effects of AHCT on physical function, body composition, QOL, energy expenditure, cytokines, and testosterone. Outcomes were assessed before (PRE) and 30 ± 10 days after (FU) AHCT in patients with multiple myeloma (n = 15) and non-Hodgkin lymphoma (n = 6). Six-minute walk test (6MWT; p = 0.014), lean mass (p = 0.002), and fat mass (p = 0.02) decreased; nausea and fatigue increased at FU (both p = 0.039). Recent weight change and steroid exposure were predictors of reduced aerobic capacity (p < 0.001). There were no significant changes in interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF), energy expenditure, or bioavailable testosterone. Alterations in cytokines, energy expenditure, and testosterone were not associated with functional impairment acutely following AHCT. Recent history of weight loss and steroid exposure were predictors of worse physical function after AHCT, suggesting that targeting nutritional status and myopathy may be viable strategies to mitigate these effects.
Collapse
Affiliation(s)
- Lindsey J Anderson
- Geriatric Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, 98108 WA, USA
| | - Chelsea Yin
- Geriatric Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, 98108 WA, USA
| | - Raul Burciaga
- Geriatric Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, 98108 WA, USA
| | - Jonathan Lee
- Geriatric Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, 98108 WA, USA
| | - Stephanie Crabtree
- Bone Marrow Transplant Unit, Veterans Affairs Puget Sound Health Care System, Seattle, 98108 WA, USA
| | - Dorota Migula
- Geriatric Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, 98108 WA, USA
| | - Kelsey Geiss-Wessel
- Geriatric Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, 98108 WA, USA
| | - Haiming M Liu
- Geriatric Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, 98108 WA, USA
- Gerontology and Geriatric Medicine, University of Washington Department of Medicine, Seattle, 98195 WA, USA
| | - Solomon A Graf
- Bone Marrow Transplant Unit, Veterans Affairs Puget Sound Health Care System, Seattle, 98108 WA, USA
- Oncology, University of Washington Department of Medicine, Seattle, 98195 WA, USA
- Fred Hutchinson Cancer Research Center, Seattle, 98109 WA, USA
| | - Thomas R Chauncey
- Bone Marrow Transplant Unit, Veterans Affairs Puget Sound Health Care System, Seattle, 98108 WA, USA
- Oncology, University of Washington Department of Medicine, Seattle, 98195 WA, USA
- Fred Hutchinson Cancer Research Center, Seattle, 98109 WA, USA
| | - Jose M Garcia
- Geriatric Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, 98108 WA, USA.
- Gerontology and Geriatric Medicine, University of Washington Department of Medicine, Seattle, 98195 WA, USA.
| |
Collapse
|
2
|
Vigano AAL, Morais JA, Ciutto L, Rosenthall L, di Tomasso J, Khan S, Olders H, Borod M, Kilgour RD. Use of routinely available clinical, nutritional, and functional criteria to classify cachexia in advanced cancer patients. Clin Nutr 2016; 36:1378-1390. [PMID: 27793524 DOI: 10.1016/j.clnu.2016.09.008] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2015] [Revised: 04/04/2016] [Accepted: 09/13/2016] [Indexed: 12/21/2022]
Abstract
BACKGROUND Cachexia is a highly prevalent syndrome in cancer and chronic diseases. However, due to the heterogeneous features of cancer cachexia, its identification and classification challenge clinical practitioners. OBJECTIVE To determine the clinical relevance of a cancer cachexia classification system in advanced cancer patients. DESIGN Beginning with the four-stage classification system proposed for cachexia [non-cachexia (NCa), pre-cachexia (PCa), cachexia (Ca) and refractory cachexia (RCa)], we assigned patients to these cachexia stages according to five classification criteria available in clinical practice: 1) biochemistry (high C-reactive protein or leukocytes, or hypoalbuminemia, or anemia), 2) food intake (normal/decreased), weight loss: 3) moderate (≤5%) or 4) significant (>5%/past six months) and 5) performance status (Eastern Cooperative Oncology Group Performance Status ≥ 3). We then determined if symptom severity, body composition changes, functional levels, hospitalizations and survival rates varied significantly across cachexia stages. RESULTS Two-hundred and ninety-seven advanced cancer patients with primary gastrointestinal and lung tumors were included. Patients were classified into Ca (36%), PCa and RCa (21%, respectively) and NCa (15%). Significant (p < 0.05) differences were observed among cachexia stages for most of the outcome measures (symptoms, body composition, handgrip strength, emergency room visits and length of hospital stays) according to cachexia severity. Survival also differed between cachexia stages (except between PCa and Ca). CONCLUSION Five clinical criteria can be used to stage cancer cachexia patients and predict important clinical, nutritional and functional outcomes. The lack of statistical difference between PCa and Ca in almost all clinical outcomes examined suggests either that the PCa group includes patients already affected by early cachexia or that more precise criteria are needed to differentiate PCa from Ca patients. More studies are required to validate these findings.
Collapse
Affiliation(s)
- Antonio A L Vigano
- McGill Nutrition and Performance Laboratory (MNUPAL), 105B, Place Vendôme, 5252 de Maisonneuve West, Montreal, Quebec, H4A 3S5, Canada; Supportive and Palliative Care, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, Quebec, H4A 3J1, Canada.
| | - José A Morais
- Geriatric Medicine, McGill University Health Centre, Royal Victoria Hospital, Room H6.61, 687 Pine Avenue West, Montreal, Quebec, H3A 1A1, Canada.
| | - Lorella Ciutto
- McGill Nutrition and Performance Laboratory (MNUPAL), 105B, Place Vendôme, 5252 de Maisonneuve West, Montreal, Quebec, H4A 3S5, Canada; School of Dietetics and Human Nutrition, McGill University, Macdonald-Stewart Building, Macdonald Campus, 21111 Lakeshore Road, Sainte-Anne-de-Bellevue, Quebec, H9X 3V9, Canada; Centre Hospitalier Universitaire Vaudois, Service d'endocrinologie, diabétologie et métabolisme, Nutrition clinique, Bureau 08/112, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
| | - Leonard Rosenthall
- Department of Radiology, McGill University Health Centre, 1650 Cedar Ave, Montreal, Quebec, H3G 1A4, Canada.
| | - Jonathan di Tomasso
- McGill Nutrition and Performance Laboratory (MNUPAL), 105B, Place Vendôme, 5252 de Maisonneuve West, Montreal, Quebec, H4A 3S5, Canada; School of Dietetics and Human Nutrition, McGill University, Macdonald-Stewart Building, Macdonald Campus, 21111 Lakeshore Road, Sainte-Anne-de-Bellevue, Quebec, H9X 3V9, Canada.
| | - Sarah Khan
- McGill Nutrition and Performance Laboratory (MNUPAL), 105B, Place Vendôme, 5252 de Maisonneuve West, Montreal, Quebec, H4A 3S5, Canada.
| | - Henry Olders
- McGill Nutrition and Performance Laboratory (MNUPAL), 105B, Place Vendôme, 5252 de Maisonneuve West, Montreal, Quebec, H4A 3S5, Canada.
| | - Manuel Borod
- Supportive and Palliative Care, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, Quebec, H4A 3J1, Canada.
| | - Robert D Kilgour
- McGill Nutrition and Performance Laboratory (MNUPAL), 105B, Place Vendôme, 5252 de Maisonneuve West, Montreal, Quebec, H4A 3S5, Canada; Department of Exercise Science, Concordia University, The Richard J. Renaud Science Complex, Room SP-165-03, 7141 Sherbrooke Street West, Montreal, Quebec, H4B 1R6, Canada.
| |
Collapse
|
3
|
Fuoco D, di Tomasso J, Boulos C, Kilgour RD, Morais JA, Borod M, Vigano A. Identifying nutritional, functional, and quality of life correlates with male hypogonadism in advanced cancer patients. Ecancermedicalscience 2015; 9:561. [PMID: 26316882 PMCID: PMC4544574 DOI: 10.3332/ecancer.2015.561] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2015] [Indexed: 11/30/2022] Open
Abstract
With the availability of a potential treatment to reverse male hypogonadism (MH), the primary aim of this case series study was to determine independent relationships between this condition and the nutritional, functional, and quality of life characteristics of advanced cancer patients (ACP). Free testosterone levels were measured in 100 male patients with advanced lung and gastrointestinal (GI) cancer. Routine blood markers of nutrition and inflammation, self-reporting questionnaires for symptom, nutrition, and functional status along with handgrip dynamometry were assessed for all patients at bedside. Almost half of this cohort underwent further assessments (body composition, lower body strength, in depth quality of life and fatigue questionnaires) at the McGill Nutrition and Performance Laboratory (mnupal.mcgill.ca). Multiple regression analyses were performed to identify independent correlations between free testosterone and the above measures. Seventy-six percent of patients were diagnosed with MH. Using multiple linear regression, low free testosterone (31.2 pmol/L) was independently associated with lower albumin (B = –3.8 g/L; 95% confidence interval CI –6.8:–0.8), muscle strength (–11.7 lbs; –20.4: –3.0) and mass in upper limbs (–0.8 kg; –1.4: –0.1), overall performance status (Eastern Cooperative Oncology Group Performance Scale, ECOG PS 0.6; 0.1:1.1), cancer-related fatigue (Brief Fatigue Inventory, BFI 16.7; 2.0: 31.3), and overall quality of life (MQoL total score –1.42; –2.5: –0.3). Thus MH seems to be highly prevalent in ACP, and it is independently associated with important nutritional, functional, and quality of life characteristics in this patient population.
Collapse
Affiliation(s)
- Domenico Fuoco
- McGill Nutrition and Performance Laboratory, McGill University Health Centre, Montreal H4A 3S5, Canada ; Division of Supportive and Palliative Care Medicine, McGill University Health Centre, Montreal H4A 3S5, Canada
| | - Jonathan di Tomasso
- Division of Supportive and Palliative Care Medicine, McGill University Health Centre, Montreal H4A 3S5, Canada
| | - Caroline Boulos
- McGill Nutrition and Performance Laboratory, McGill University Health Centre, Montreal H4A 3S5, Canada
| | - Robert D Kilgour
- McGill Nutrition and Performance Laboratory, McGill University Health Centre, Montreal H4A 3S5, Canada ; Department of Exercise Science, Concordia University, Montreal H4B 1R6, Canada
| | - Jose A Morais
- McGill Nutrition and Performance Laboratory, McGill University Health Centre, Montreal H4A 3S5, Canada ; Department of Geriatric Medicine, McGill University, Montreal H4A 3S5, Canada
| | - Manuel Borod
- McGill Nutrition and Performance Laboratory, McGill University Health Centre, Montreal H4A 3S5, Canada ; Division of Supportive and Palliative Care Medicine, McGill University Health Centre, Montreal H4A 3S5, Canada
| | - Antonio Vigano
- McGill Nutrition and Performance Laboratory, McGill University Health Centre, Montreal H4A 3S5, Canada ; Division of Supportive and Palliative Care Medicine, McGill University Health Centre, Montreal H4A 3S5, Canada
| |
Collapse
|